Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
NCT06566443Phase 1Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of honokiol in non-small cell lung cancer (NSCLC), sponsored by Houston Methodist Research Institute. Primary endpoint: Maximum Tolerated Dose up to 21 days. Started Feb 2025; status: recruiting.
02
Drugs
honokiol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06566443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566443.